Immunis.AI Reports Results of a Prospective Study of its RNAseq-Based Liquid-Biopsy in Early-Stage Prostate Cancer
Study Findings Demonstrate the Company’s Proprietary Immunogenomic Platform Enhances Cancer Detection and Risk Stratification ROYAL OAK, Mich.–(BUSINESS WIRE)–Immunis.AI, Inc., an immunogenomics platform company developing noninvasive blood-based tests to optimize patient care, today announced the publication of pivotal results from its clinical trial, Evaluation of an RNAseq-based Immunogenomic Liquid Biopsy Approach in Early-Stage Prostate Cancer, in […]